T-Cell Receptor and Immune Gene Expression Pharmacodynamics for Durvalumab Alone and with Tremelimumab or Bevacizumab in Unresectable Hepatocellular Carcinoma
These findings suggest that STRIDE and D + B have distinct, and potentially complementary, mechanisms of action in uHCC.
Authors
- Robin Kate Kelley (ORCID: https://orcid.org/0000-0002-1984-2430)
- John F. Kurland (ORCID: https://orcid.org/0000-0003-0863-2486)
- Patricia McCoon (ORCID: https://orcid.org/0000-0002-1397-6446)
- James Conway (ORCID: https://orcid.org/0000-0002-1725-8193)
- Young S. Lee (ORCID: https://orcid.org/0000-0002-1692-4959)
Institutions
- University of California, San Francisco (US)
- AstraZeneca (South Korea) (KR)
- AstraZeneca (Netherlands) (NL)
- AstraZeneca (Brazil) (BR)
- AstraZeneca (United States) (US)
- UCSF Helen Diller Family Comprehensive Cancer Center (US)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2025-12-08
- DOI
- https://doi.org/10.1158/1078-0432.ccr-25-1592
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- AstraZeneca